Symptoms & Subtypes: Functional vs. Non-Functional pNETs
At a Glance
Pancreatic neuroendocrine tumors (pNETs) are classified as functional if they overproduce hormones that cause specific symptoms, or non-functional if they do not. Non-functional pNETs are more common and usually only cause symptoms like abdominal pain or jaundice when they grow large.
When you are diagnosed with a [pancreatic neuroendocrine tumor (-1 “Understanding Your pNET Diagnosis”), one of the first things your medical team will determine is whether the tumor is functional or non-functional. This classification is based entirely on whether the tumor cells are overproducing hormones that cause specific symptoms in your body [1][2].
Functional vs. Non-Functional: The Key Difference
The “neuroendocrine” cells that make up these tumors are naturally designed to produce hormones. In a functional pNET, the tumor cells are “active” and pump out large amounts of a specific hormone, such as insulin or gastrin, into your bloodstream [1]. These excess hormones cause distinct “syndromes” or sets of symptoms that often lead to a diagnosis [3].
In contrast, a non-functional pNET (NF-pNET) either does not produce hormones at all or produces them in such small amounts that they don’t cause a noticeable syndrome [1]. These are actually the most common type, representing 50% to 91% of all cases [4][5]. Because they don’t cause hormonal symptoms, they are often discovered “incidentally”—meaning they are found by accident on a scan for something else, like a kidney stone or an injury [6].
Specific Functional Subtypes
If your tumor is functional, it is named after the specific hormone it produces. Each has its own unique “calling card” of symptoms:
- Insulinoma (Insulin): The most common functional pNET [7]. It overproduces insulin, causing hypoglycemia (dangerously low blood sugar). Patients often experience the Whipple Triad: symptoms like shakiness, confusion, or sweating; a documented low blood sugar level; and immediate relief after eating sugar [8][9].
- Gastrinoma (Gastrin): Produces excess gastrin, leading to Zollinger-Ellison Syndrome. This causes the stomach to make too much acid, resulting in severe, painful stomach ulcers and chronic diarrhea [10][11].
- Glucagonoma (Glucagon): Produces glucagon, often leading to the “4Ds” syndrome: Diabetes (high blood sugar), Dermatitis (a painful, migrating red rash called NME), Deep vein thrombosis (blood clots), and Depression or weight loss [12].
- VIPoma (Vasoactive Intestinal Peptide): Produces VIP, which leads to WDHA syndrome: Watery Diarrhea, Hypokalemia (low potassium), and Achlorhydria (low stomach acid) [11].
- Somatostatinoma (Somatostatin): An extremely rare tumor that produces somatostatin, which can cause a “shutdown” of digestive processes, leading to diabetes, gallstones, and oily stools (steatorrhea) [13].
Symptoms of Non-Functional Tumors
Because non-functional tumors don’t send out hormone signals, they are usually silent until they grow large enough to press on nearby organs. This is known as mass-effect [1][14]. Symptoms of mass-effect depend on where the tumor is located:
- Jaundice: If a tumor in the “head” of the pancreas presses on the bile duct, it can cause yellowing of the skin and eyes [14].
- Abdominal Pain: A large tumor can cause a deep, dull ache in the belly or back [14].
- Bowel Obstruction: If the tumor presses on the stomach or intestines, it can cause nausea, vomiting, or a feeling of being full very quickly [14].
Whether your tumor is functional or non-functional, the goal of your care team is the same: to use the best treatment options to manage the tumor itself while ensuring any symptoms—whether from hormones or mass-effect—are carefully controlled [15].
Common questions in this guide
What is the difference between a functional and non-functional pNET?
How do doctors test for a functional pNET?
What are the symptoms of a non-functional pNET?
What is an insulinoma and what symptoms does it cause?
Get notified when new evidence is published on Neuroendocrine tumor of pancreas.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Animal models of spontaneous pancreatic neuroendocrine tumors.
Yu R
Molecular and cellular endocrinology 2016; (421()):60-7.
PMID: 26261055 - 2
Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review.
Keretić D, Bašković M
Diagnostics (Basel, Switzerland) 2025; (15(17)) doi:10.3390/diagnostics15172176.
PMID: 40941664 - 3
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.
Falconi M, Eriksson B, Kaltsas G, et al.
Neuroendocrinology 2016; (103(2)):153-71 doi:10.1159/000443171.
PMID: 26742109 - 4
Pancreatic neuroendocrine tumors.
Varas Lorenzo M, Cugat Andorra E, Capdevila Castillón J
Revista espanola de enfermedades digestivas 2017; (109(6)):480-481 doi:10.17235/reed.2017.4725/2016.
PMID: 28253729 - 5
Islet Cell Tumors of the Pancreas.
Amin S, Kim MK
Gastroenterology clinics of North America 2016; (45(1)):83-100.
PMID: 26895682 - 6
Surgery or active surveillance for pNETs < 2 cm: Preliminary results from a single center Brazilian cohort.
Arra DASM, Ribeiro HSC, Henklain G, et al.
Journal of surgical oncology 2022; (126(1)):168-174 doi:10.1002/jso.26931.
PMID: 35689580 - 7
An observational analysis of insulinoma from a single institution.
Shao S, Zeng Z, Hu S
QJM : monthly journal of the Association of Physicians 2018; (111(4)):237-241 doi:10.1093/qjmed/hcy006.
PMID: 29319794 - 8
Technical aspects of paediatric robotic pancreatic enucleation based on a case of an insulinoma.
Schulte Am Esch J, Krüger M, Barthlen W, et al.
The international journal of medical robotics + computer assisted surgery : MRCAS 2021; (17(6)):e2317 doi:10.1002/rcs.2317.
PMID: 34297475 - 9
Ectopic insulinoma: case report.
Sun M, Luo Y, You Y, et al.
BMC surgery 2019; (19(1)):197 doi:10.1186/s12893-019-0661-y.
PMID: 31852474 - 10
Current Medical Controversies in Zollinger-Ellison Syndrome.
Jensen RT, Ramos-Alvarez I, Norton JA
Biomedicines 2025; (13(12)) doi:10.3390/biomedicines13123051.
PMID: 41463062 - 11
Clinical treatment of gastrinoma: A case report and review of the literature.
Zhang WD, Liu DR, Wang P, et al.
Oncology letters 2016; (11(5)):3433-3437 doi:10.3892/ol.2016.4397.
PMID: 27123130 - 12
Glucagonoma and the glucagonoma syndrome.
Song X, Zheng S, Yang G, et al.
Oncology letters 2018; (15(3)):2749-2755 doi:10.3892/ol.2017.7703.
PMID: 29435000 - 13
Characteristics, therapy, and outcome of rare functioning pancreatic neuroendocrine neoplasms.
Albers MB, Sevcik M, Wiese D, et al.
Scientific reports 2024; (14(1)):18507 doi:10.1038/s41598-024-68290-1.
PMID: 39122816 - 14
Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report.
Kumar A, Tanwar S, Gupta S, et al.
Exploration of targeted anti-tumor therapy 2022; (3(3)):392-397 doi:10.37349/etat.2022.00089.
PMID: 36045912 - 15
The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8-institution study from the US Neuroendocrine Tumor Study Group.
Zaidi MY, Lopez-Aguiar AG, Poultsides GA, et al.
Journal of surgical oncology 2019; (119(1)):5-11 doi:10.1002/jso.25306.
PMID: 30481383
This page provides educational information about functional and non-functional pancreatic neuroendocrine tumors. It does not replace professional medical advice, and you should always consult your oncologist regarding your specific diagnosis and symptoms.